Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMDLN9E)

• Drug Name: BALANOL Drug Info
• Synonyms: balanol; 63590-19-2; Azepinostatin; CHEMBL60254; Balanol, 1; 2-[2,6-dihydroxy-4-[(3R,4R)-3-[(4-hydroxybenzoyl)amino]azepan-4-yl]oxycarbonylbenzoyl]-3-hydroxybenzoic acid; BA1; (-)-Balanol; (3R-trans)-Balanol; AC1NRA6W; SCHEMBL62128; MEGxm0_000504; GTPL8142; BDBM3149; Acyclic Balanol Analog (-)-1; BDBM36607; ACon0_001438; ZINC3871640; MCULE-9310625171; 167937-47-5; FT-0662471; 33879-EP2275420A1; 33879-EP2295416A2; 33879-EP2295055A2; 33879-EP2311453A1; 33879-EP2305642A2; 33879-EP2298764A1; 33879-EP2298765A1; 33879-EP2298748A2
• Cross-matching ID:
  PubChem CID: 5287736
  CAS Number: CAS 63590-19-2
  TTD Drug ID: DMDLN9E

Molecule-Related Drug Atlas

Drug(s) Targeting Protein kinase C alpha (PRKCA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sodium phenylbutyrate	DMXLBCQ	Spinal muscular atrophy	8B61	Approved	[4]
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[5]
PMID28460551-Compound-3	DMA1FRM	N. A.	N. A.	Patented	[6]
ISIS 3521	DMZFS69	N. A.	N. A.	Discontinued in Phase 2	[7]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[8]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[9]
Acteoside	DM0YHKB	Nephritis	GB40	Terminated	[10]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[11]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[12]
CI-1040	DMF3DZX	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting PRKACA messenger RNA (PRKACA mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VFEDEOUBYBLDKN-AAFJCEBUSA-N	DMH9ION	N. A.	N. A.	Patented	[14]
XHPNYYOUZWOWNT-PYUWXLGESA-N	DM5Q93Y	N. A.	N. A.	Patented	[14]
AGGGWZCOULSEER-PYUWXLGESA-N	DM2L83Y	N. A.	N. A.	Patented	[14]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[15]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[16]
NM-PP1	DMS8H5Q	Discovery agent	N.A.	Investigative	[17]
ISIS 102633	DMWT7BK	Discovery agent	N.A.	Investigative	[18]
ISIS 102604	DMZ6X9B	Discovery agent	N.A.	Investigative	[18]
ISIS 102619	DMXH9IT	Discovery agent	N.A.	Investigative	[18]
ISIS 102462	DMXNC0B	Discovery agent	N.A.	Investigative	[18]

Drug(s) Targeting PKC-eta messenger RNA (PRKCH mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[19]
PROSTRATIN	DM1HMJ5	Human immunodeficiency virus infection	1C62	Investigative	[20]
8-Octyl-benzolactam-V9	DM4Z15M	Discovery agent	N.A.	Investigative	[21]
ISIS 6445	DMXJ4SO	Discovery agent	N.A.	Investigative	[22]
ISIS 6432	DMQHN43	Discovery agent	N.A.	Investigative	[22]
ISIS 6553	DM5L387	Discovery agent	N.A.	Investigative	[22]
ISIS 6581	DMEAVPQ	Discovery agent	N.A.	Investigative	[22]
ISIS 6442	DM7KSRG	Discovery agent	N.A.	Investigative	[22]
ISIS 6434	DMNVLE2	Discovery agent	N.A.	Investigative	[22]
ISIS 6431	DMEUCI2	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting Protein kinase C beta (PRKCB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Enzastaurin	DM5H0R9	Diffuse large B-cell lymphoma	2A81	Phase 3	[23]
RUBOXISTAURIN HYDROCHLORIDE	DMQOCD8	Lymphoma	2A80-2A86	Phase 3	[24]
Sotrastaurin acetate	DME53YS	Renal transplantation	NE84	Phase 2	[5]
LY333531	DMGMC8H	Solid tumour/cancer	2A00-2F9Z	Phase 2	[25]
MS-553	DM7ER9J	Chronic lymphocytic leukaemia	2A82.0	Phase 1	[26]
Linetastine	DMF8B62	Rhinitis	FA20	Discontinued in Phase 2	[27]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[8]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[9]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[11]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[19]

Drug(s) Targeting Protein kinase C gamma (PRKCG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Midostaurin	DMI6E0R	Acute myeloid leukaemia	2A60	Approved	[28]
RO-320432	DMFZ1YW	N. A.	N. A.	Terminated	[8]
LY-317644	DMM20PI	N. A.	N. A.	Terminated	[9]
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[11]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[29]
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione	DMDO175	Discovery agent	N.A.	Investigative	[30]
3,4-diphenyl-1H-pyrrole-2,5-dione	DMPK6YT	Discovery agent	N.A.	Investigative	[30]
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione	DMGC7RY	Discovery agent	N.A.	Investigative	[30]
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione	DM3EV9N	Discovery agent	N.A.	Investigative	[30]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[19]

Drug(s) Targeting PKC-delta messenger RNA (PRKCD mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[29]
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[19]
PROSTRATIN	DM1HMJ5	Human immunodeficiency virus infection	1C62	Investigative	[20]
8-Octyl-benzolactam-V9	DM4Z15M	Discovery agent	N.A.	Investigative	[21]
Go 6983	DMKVTZN	Discovery agent	N.A.	Investigative	[31]
Diheptan-3-yl 5-(hydroxymethyl)isophthalate	DMBAY7P	Discovery agent	N.A.	Investigative	[32]
Dihexan-3-yl 5-(hydroxymethyl)isophthalate	DM8TBQ9	Discovery agent	N.A.	Investigative	[32]
ISIS 10310	DMT6H9S	Discovery agent	N.A.	Investigative	[22]
ISIS 17252	DMW40NK	Discovery agent	N.A.	Investigative	[33]
ISIS 10303	DM205TE	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting Casein kinase II alpha (CSNK2A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CX-4945	DMWE7B9	Coronavirus infection	1D92	Phase 2	[34]
EMODIN	DMAEDQG	Coronavirus Disease 2019 (COVID-19)	1D6Y	Terminated	[35]
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[15]
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole	DMN9YOB	Discovery agent	N.A.	Investigative	[35]
ELLAGIC ACID	DMX8BS5	Discovery agent	N.A.	Investigative	[35]
APIGENIN	DMI3491	Discovery agent	N.A.	Investigative	[35]
PMID24900749C1a	DMZPUSO	Discovery agent	N.A.	Investigative	[36]
AdoC(Dpr)2AlaArg6	DM2TWSZ	Discovery agent	N.A.	Investigative	[37]
PMID22115617C2c	DMX5UKA	Discovery agent	N.A.	Investigative	[38]
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole	DM3JB6S	Discovery agent	N.A.	Investigative	[35]

Drug(s) Targeting PKC-zeta messenger RNA (PRKCZ mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LY-326449	DMN53M4	Discovery agent	N.A.	Investigative	[19]
Go 6983	DMKVTZN	Discovery agent	N.A.	Investigative	[31]
ISIS 9008	DMQDZF2	Discovery agent	N.A.	Investigative	[22]
ISIS 9022	DM7TRSB	Discovery agent	N.A.	Investigative	[22]
ISIS 9023	DMO2V5C	Discovery agent	N.A.	Investigative	[22]
ISIS 9007	DMGK2TQ	Discovery agent	N.A.	Investigative	[22]
ISIS 9025	DMAQ7XH	Discovery agent	N.A.	Investigative	[22]

Drug(s) Targeting cAMP protein kinase type II-beta (PRKAR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[15]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[16]
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[39]
AdoC(Dpr)2AlaArg6	DM2TWSZ	Discovery agent	N.A.	Investigative	[37]
AdcAhxArg4NH(CH2)6NH2	DMSYMRJ	Discovery agent	N.A.	Investigative	[40]
AdcAhxArg4Lys-PEGOMe	DMQ2C8X	Discovery agent	N.A.	Investigative	[40]
AdoC(GABA)Arg6	DMMWNPT	Discovery agent	N.A.	Investigative	[37]
AdcAhxArg4Lys(biotin)-PEG-OMe	DMZYJHV	Discovery agent	N.A.	Investigative	[40]
AdoC(Aun)Arg6	DMDLHAB	Discovery agent	N.A.	Investigative	[37]
AdoCGlyArg6	DMVQJP0	Discovery agent	N.A.	Investigative	[37]

Drug(s) Targeting Fungal Protein kinase A (Fung ypkA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
4-[(3,5-diamino-1H-pyrazol-4-yl)diazenyl]phenol	DMSKJ1X	Discovery agent	N.A.	Investigative	[15]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[16]
PMID20005102C1	DMMESBW	Discovery agent	N.A.	Investigative	[41]
[3H]cAMP	DMZRQU7	Discovery agent	N.A.	Investigative	[42]
PMID19364658C33	DMSE1C3	Discovery agent	N.A.	Investigative	[43]
BX-912	DMZA45C	Discovery agent	N.A.	Investigative	[44]
BX-795	DMRIMLJ	Discovery agent	N.A.	Investigative	[44]
chelerythrine	DMCP1G9	Discovery agent	N.A.	Investigative	[45]
PMID21742770C1	DME3JMH	Discovery agent	N.A.	Investigative	[46]
Rp-adenosine 3',5'-cyclic monophosphothioate triethylamine (Rp-cAMPS)	DM1JWGH	Discovery agent	N.A.	Investigative	[47]

Drug(s) Targeting PKC-epsilon messenger RNA (PRKCE mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RO-316233	DMAGLPW	Discovery agent	N.A.	Investigative	[48]
Bisindolylmaleimide-I	DMOQJZC	Discovery agent	N.A.	Investigative	[29]
PROSTRATIN	DM1HMJ5	Human immunodeficiency virus infection	1C62	Investigative	[20]
8-Octyl-benzolactam-V9	DM4Z15M	Discovery agent	N.A.	Investigative	[21]
chelerythrine	DMCP1G9	Discovery agent	N.A.	Investigative	[45]
ISIS 7942	DMN0A1R	Discovery agent	N.A.	Investigative	[22]
ISIS 7948	DMYZE8R	Discovery agent	N.A.	Investigative	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
cAMP protein kinase type II-beta (PRKAR2B)	TTW4Y2M	KAP3_HUMAN	Inhibitor	[1]
Casein kinase II alpha (CSNK2A1)	TTER6YH	CSK21_HUMAN	Inhibitor	[2]
Fungal Protein kinase A (Fung ypkA)	TTYVI76	Q56921_YEREN	Inhibitor	[1]
PKC-delta messenger RNA (PRKCD mRNA)	TT7A1BO	KPCD_HUMAN	Inhibitor	[3]
PKC-epsilon messenger RNA (PRKCE mRNA)	TT57MT2	KPCE_HUMAN	Inhibitor	[3]
PKC-eta messenger RNA (PRKCH mRNA)	TTONI0R	KPCL_HUMAN	Inhibitor	[3]
PKC-zeta messenger RNA (PRKCZ mRNA)	TTBSN0L	KPCZ_HUMAN	Inhibitor	[3]
PRKACA messenger RNA (PRKACA mRNA)	TT5U49F	KAPCA_HUMAN	Inhibitor	[1]
Protein kinase C alpha (PRKCA)	TTFJ8Q1	KPCA_HUMAN	Inhibitor	[3]
Protein kinase C beta (PRKCB)	TTYPXQF	KPCB_HUMAN	Inhibitor	[3]
Protein kinase C gamma (PRKCG)	TTRFOXJ	KPCG_HUMAN	Inhibitor	[3]

References

• [1] Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry. J Med Chem. 2005 Sep 8;48(18):5613-38. Address
• [2] Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A. J Med Chem. 1996 Dec 20;39(26):5215-27.
• [3] Evaluation of differential hypoxic cytotoxicity and electrochemical studies of nitro 5-deazaflavins, Bioorg. Med. Chem. Lett. 5(18):2155-2160 (1995).
• [4] Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.Mol Cancer Ther. 2013 Aug;12(8):1393-401.
• [5] Emerging drugs for psoriasis. Expert Opin Emerg Drugs. 2009 Mar;14(1):145-63.
• [6] Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
• [7] Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.Lung Cancer.2006 May;52(2):173-80.
• [8] Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain, Bioorg. Med. Chem. Lett. 4(11):1303-1308 (1994).
• [9] Synthesis of bisindolylmaleimide macrocycles, Bioorg. Med. Chem. Lett. 5(18):2093-2096 (1995).
• [10] Phenylethanoid glycosides from Digitalis purpurea and Penstemon linarioides with PKCalpha-inhibitory activity. J Nat Prod. 1998 Nov;61(11):1410-2.
• [11] Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides. J Med Chem. 1992 Jan;35(1):177-84.
• [12] Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7-tetrabromobenzimidazole. J Med Chem. 2004 Dec 2;47(25):6239-47.
• [13] Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
• [14] Purine derivatives. US8846696.
• [15] 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem. 2006 Nov 2;49(22):6500-9.
• [16] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
• [17] The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
• [18] US patent application no. 6,248,586, Antisense modulation of PKA catalytic subunit C-alpha expression.
• [19] (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H... J Med Chem. 1996 Jul 5;39(14):2664-71.
• [20] A nonpromoting phorbol from the samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. J Med Chem. 1992 May 29;35(11):1978-86.
• [21] Design and synthesis of 8-octyl-benzolactam-V9, a selective activator for protein kinase C epsilon and eta. J Med Chem. 2006 May 4;49(9):2681-8.
• [22] US patent application no. 5,959,096, Antisense oligonucleotides against human protein kinase C.
• [23] The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines. Leuk Lymphoma. 2008 Jul;49(7):1374-83.
• [24] Ruboxistaurin: LY 333531. Drugs R D. 2007;8(3):193-9.
• [25] Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes. 2003 Feb;52(2):512-8.
• [26] ClinicalTrials.gov (NCT03492125) A Study Of The Selective PKC-beta Inhibitor MS- 553. U.S. National Institutes of Health.
• [27] Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol. 2002 May;133(5):693-8.
• [28] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [29] Protein kinase C epsilon regulates gamma-aminobutyrate type A receptor sensitivity to ethanol and benzodiazepines through phosphorylation of gamma2... J Biol Chem. 2007 Nov 9;282(45):33052-63.
• [30] Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.
• [31] Inhibition of protein kinase C mu by various inhibitors. Differentiation from protein kinase c isoenzymes. FEBS Lett. 1996 Aug 26;392(2):77-80.
• [32] Design, synthesis, and biological activity of isophthalic acid derivatives targeted to the C1 domain of protein kinase C. J Med Chem. 2009 Jul 9;52(13):3969-81.
• [33] US patent application no. 6,235,723, Antisense oligonucleotide modulation of human protein kinase C-.delta. expression.
• [34] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [35] Structural insight into human CK2alpha in complex with the potent inhibitor ellagic acid. Bioorg Med Chem Lett. 2009 Jun 1;19(11):2920-3.
• [36] Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo. ACS Med Chem Lett. 2013 Jul 3;4(8):800-5.
• [37] Adenosine-5'-carboxylic acid peptidyl derivatives as inhibitors of protein kinases. Bioorg Med Chem Lett. 1999 May 17;9(10):1447-52.
• [38] CK2alpha and CK2alpha' subunits differ in their sensitivity to 4,5,6,7-tetrabromo- and 4,5,6,7-tetraiodo-1H-benzimidazole derivatives. Eur J Med Chem. 2012 Jan;47(1):345-50.
• [39] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [40] Liquid-phase synthesis of a pegylated adenosine-oligoarginine conjugate, cell-permeable inhibitor of cAMP-dependent protein kinase. Bioorg Med Chem Lett. 2003 Sep 15;13(18):3035-9.
• [41] 2,3,5-Trisubstituted pyridines as selective AKT inhibitors. Part II: Improved drug-like properties and kinase selectivity from azaindazoles. Bioorg Med Chem Lett. 2010 Jan 15;20(2):679-83.
• [42] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1694).
• [43] Identification and SAR of squarate inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK-2). Bioorg Med Chem. 2009 May 1;17(9):3342-51.
• [44] Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem. 2005 May 20;280(20):19867-74.
• [45] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [46] A Potent and Selective Quinoxalinone-Based STK33 Inhibitor Does Not Show Synthetic Lethality in KRAS-Dependent Cells. ACS Med Chem Lett. 2012 Dec 13;3(12):1034-1038.
• [47] Inhibition of protein kinase A activity interferes with long-term, but not short-term, memory of conditioned taste aversions. Behav Neurosci. 2002 Dec;116(6):1070-4.
• [48] Synthesis of anilino-monoindolylmaleimides as potent and selective PKCbeta inhibitors. Bioorg Med Chem Lett. 2004 Oct 18;14(20):5171-4.